Abemaciclib
Top View
- Injectable and Health Care Administered Oncology Medical Drug Criteria Through Preferred (Optional)
- FDA-Approved Drugs Under Investigation in Multiple Myeloma for Actionable Targets
- 5.01.540 Miscellaneous Oncology Drugs
- Statistical Analysis Plan Version 1
- Verzenios, INN-Abemaciclib
- Appendix B - Product Name Sorted by Applicant
- January 2021 Forward-Looking Statements and Disclaimer
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Identification of Synergistic Drug Combinations Using Breast Cancer
- An Overview of the Recently Approved Small-Molecules Anticancer Drugs in the Past Decade
- The Top 15 Best-Selling Cancer Drugs in 2022 by Phil Taylor
- August 2021 Forward-Looking Statements and Disclaimer
- Focus on Triple-Negative Breast Cancer: Potassium Channel Expression and Clinical Correlates
- Self-Administered Specialty Drug List
- Stromal Senescence by Prolonged CDK4/6 Inhibition Potentiates Tumor Growth Xiangnan Guan1, Kyle M
- Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
- Abemaciclib, a Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
- Adjuvant Abemaciclib‑Induced Pneumonitis: a Case Report and Review of the Literature